0
0
0
0
1
2
3
$0
Is Dexcom solid or fragile? The Finex Financial Health Scanner reads DXCM's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $4.7B |
|---|---|
| Net income | $836.3M |
| Operating margin | 19.6% |
| Net margin | 17.9% |
| Cash and investments | $2.0B |
| Total debt | $1.2B |
| Free cash flow | $811.9M |
| Revenue growth (1 year) | 15.6% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.